← Back to Analyst Consensus 
RANI Buy
Rani Therapeutics Holdings, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Aug 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 18, 2026 | Chardan Capital | initiate | — → Buy | — | 47% |
| May 20, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 1, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 27, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 20, 2025 | Maxim Group | maintain | Buy → Buy | $10 | 42% |
| May 16, 2025 | Oppenheimer | maintain | Outperform → Outperform | $4 | 52% |
| Apr 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Feb 26, 2025 | Canaccord Genuity | maintain | Buy → Buy | $9 | 48% |
| Feb 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Nov 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Oct 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 16, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Aug 2, 2024 | Oppenheimer | initiate | — → Outperform | $17 | 52% |
| Jun 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Jun 14, 2024 | Maxim Group | initiate | — → Buy | $15 | 42% |
| Jun 13, 2024 | Rodman & Renshaw | initiate | — → Buy | $10 | 40% |
| May 9, 2024 | BTIG | maintain | Buy → Buy | $14 | 52% |
| May 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Mar 27, 2024 | Canaccord Genuity | maintain | Buy → Buy | $9 | 48% |
| Mar 25, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Feb 6, 2024 | Wedbush | reiterate | Outperform → Outperform | $8 | 58% |
| Nov 9, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $16 | 44% |
| Sep 20, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Sep 8, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Aug 21, 2023 | B of A Securities | maintain | Buy → Buy | $17 | 53% |
| Aug 17, 2023 | Wedbush | reiterate | Outperform → Outperform | $20 | 58% |
| Aug 14, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Jun 6, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| May 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| Mar 23, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $22 | 44% |
| Oct 11, 2022 | UBS | initiate | — → Buy | $15 | 54% |
| Jul 27, 2022 | HC Wainwright & Co. | initiate | — → Buy | $22 | 44% |
| Jun 13, 2022 | Wedbush | initiate | — → Outperform | $28 | 58% |
| Aug 25, 2021 | BTIG | initiate | — → Buy | $24 | 52% |
| Aug 24, 2021 | B of A Securities | initiate | — → Buy | $23 | 53% |
| Aug 24, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $23 | 50% |
| Aug 24, 2021 | Stifel | initiate | — → Buy | $24 | 53% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days